12-month clinical outcomes after Magmaris percutaneous coronary intervention in a real-world cohort of patients: Results from the CardioHULA registry

Editorial: Reviews in bioresorbable scaffold

“…Among these, myocardial infarction, nontarget-lesion revascularization, and in-stent thrombosis were reported within the first 30 days after discharge. These findings are per the findings of Abellas-Sequeiros et al ( 3 ) reporting the safety and efficacy of magnesium-based BRS (Magmaris) with target lesion failure (TLF) of 4.7% at 12 months. The systematic review and meta-analysis by Wan et al reported a significantly higher in-stent diameter stenosis of BRS compared with metallic DES within 1 year with a similar risk of target lesion revascularization and cardiac death.…”

“…However, along with various advantages, procedural technical difficulties, intraluminal scaffold dismantling, and higher early rates of scaffold thrombosis and target vessel-related myocardial infarction, (TVMI) particularly in small vessels, coexists. A study by Abellas-Sequeiros et al ( 3 ) reported target lesion failure (TLF) of 4.7% at 12 months after magnesium-based BRS (Magmaris TM , Biotronik AG, Switzerland) deployment; however, a randomized controlled trial by Stone et al ( 4 ) reported a 3% greater absolute 5-year rate of TLF after polymer-based BRS (Absorb TM , Abbott Vascular, USA) compared with cobalt-chromium everolimus-eluting stents and a metanalysis by Wan et al reported significantly higher in-stent diameter stenosis within 1 year with a similar risk of target lesion revascularization and cardiac death with polymer- and magnesium-based BRS. These results warrant more studies to evaluate the pros and cons of BRS and their use in reducing the risk of adverse events and improving the clinical outcomes and the long-term prognosis in patients with ischemic events ( 5 ).…”

Long-Term Outcomes After Implantation of Magnesium-Based Bioresorbable Scaffolds—Insights From an All-Comer Registry

“…To put our results into perspective, most of the published studies highlighted the safety and performance of the Magmaris™ scaffold ( 11 – 15 , 20 , 21 , 32 ). The most recent BIOSOLVE-IV study showed excellent device and procedure success as well as remarkably good outcomes up to 24 months in a low-risk population ( 13 , 32 ).…”

“…So far, a series of non-randomized, controlled studies, including the BIOTRONIKS – Safety and Performance in de NOvo Lesion of NatiVE Coronary Arteries With Magmaris (BIOSOLVE) I-IV trials, showed promising outcomes after treatment with the Mg-BRS, including low rates of target lesion failure (TLF) (<5%) and ScT (<1%) ( 11 – 15 , 20 , 21 ). But, there have also been published cases, which highlighted the collapse and early dismantling of this device lately ( 22 , 23 ).…”